Subject(s)
Glutathione Transferase/genetics , Multiple Myeloma , Polymorphism, Single Nucleotide , Stem Cell Transplantation , Thalidomide/administration & dosage , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor Receptor-2/genetics , Autografts , Disease-Free Survival , Female , Humans , Male , Multiple Myeloma/genetics , Multiple Myeloma/mortality , Multiple Myeloma/therapy , Survival RateSubject(s)
Glutathione S-Transferase pi/genetics , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/mortality , Mutation, Missense , Polymorphism, Genetic , Amino Acid Substitution , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biomarkers, Tumor , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Prednisone/administration & dosage , Prospective Studies , Rituximab , Survival Rate , Translational Research, Biomedical , Vincristine/administration & dosageSubject(s)
Lymphoma, Follicular/diagnosis , Lymphoma, Follicular/genetics , Polymorphism, Single Nucleotide , Vascular Endothelial Growth Factor A/genetics , Adult , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Case-Control Studies , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/mortality , Male , Middle Aged , Prednisone/therapeutic use , Prognosis , Rituximab , Survival Analysis , Treatment Outcome , Vincristine/therapeutic useABSTRACT
BACKGROUND: Peripheral blood progenitor cells (PBPC) collection after high dose chemotherapy can be influenced by several factors. We searched for parameters that may predict the best day to start harvesting of PBPC in order to collect most CD34+ cells with the least number of aphereses. METHODS: We studied patients who underwent mobilization chemotherapy for autologous transplantation. The influence of age, sex, diagnosis, number of previous chemotherapy cycles, peripheral blood (PB) counts at day of mobilization (D0), day of neutrophils <1.0 x 10(9) l(-1) and day of nadir and interval between both (delta) on harvesting was investigated. Multivariate linear correlation models were built to predict the best harvesting with principles of parsimony. In patients where sequential CD34+ cell count was performed, the theoretical day of peak was calculated by interpolation in polynomial regression. RESULTS: One hundred and thirty four patients entered the analysis: 36 Hodgkin's lymphoma (HL), 65 B-large cell lymphoma (NHL) and 33 multiple myeloma (MM). Day of harvesting correlated with nr CHT, hemoglobin on D0, day of granulocytes <1.0 x 10(9) l(-1), delta and dosis of mobilization therapy. The day of CD34+ peak could be calculated by the formula = (-0.41) x Hemoglobin D0 + (day peripheral CD34+ cells = 10 x 10(6) microl(-1)) x 0.99 + 7.8. This model could explain 81% of the variance of the peak day and was stable by bootstrap resampling. Day of peripheral CD34+ cells = 10 x 10(6) microl(-1) preceded the calculated peak by 3-9 days. CONCLUSIONS: Although the day of best collection can be predicted using only sequential PB counts after mobilization chemotherapy, a model of prediction using peripheral CD34+ cell count is important especially for optimizing collection in poor mobilizing patients.
